(OTC: HBRM) Launches in the Trillion Dollar Global Alternative Medicine Sector
NEW YORK, NY -- (Marketwire)
06/01/10
Herborium Group, Inc. (PINKSHEETS: HBRM) announced that they are focusing their efforts on developing aggressive routes to tapping into the over the counter alternative medicine and complementary medicine market.
Plants have been used as a source of medicine throughout history and continue to serve as the basis for many pharmaceuticals used today. Although the modern pharmaceutical industry was born from botanical medicine, synthetic approaches to drug discovery have become standard. However, this modern approach has led to a decline in new drug development in recent years and a growing market for botanical therapeutics that are currently available as dietary supplements, drugs, or botanical drugs. Herborium initially aims to take on some of the most wide reaching afflictions that affect Americans, acne and benign prostate hyperplasia (BPH). These two focuses open up a 77 billion dollar market.
For more information, please visit www.smallcapsociety.com/hbrm.php
Other active stocks are Simcere Pharmaceutical Group (NYSE: SCR), China Sky One Medical (NASDAQ: CSKI) and Tianyin Pharmaceutical Co (AMEX: TPI)
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.
Eric Jensen
www.ionewswire.com
AI
